PRODUCT TYPES – Page 8

Chain of identity breach during scale-up: regulatory risk assessment and CAPA

The first step in addressing a potential chain of identity breach during scale-up is identifying the symptoms or signals that may suggest a deviation has occurred. Symptoms can manifest in…

API endotoxin risk in sterile API after drying cycle optimization: how to justify reprocessing vs rejection to FDA/EMA inspectors

The first indication that there may be an endotoxin risk is often an Out of Specification (OOS) test result during routine monitoring of end-product samples. Beyond OOS results, symptoms may…

Vector potency drift during ATMP manufacturing: inspection-ready investigation package

Identifying the early symptoms of vector potency drift is essential to mitigating potential risks. Common signals that may indicate a drift include:Click to read the full article.

API stability failure at accelerated conditions during FDA inspection readiness: supplier qualification gaps and incoming testing upgrades to close the loop

Identifying the symptoms of API stability failure is the first step in a successful investigation. Symptoms may manifest as:Click to read the full article.

Cryopreservation failure during ATMP manufacturing: inspection-ready investigation package

Identifying early symptoms of potential cryopreservation failure is key to mitigation. The following signals are commonly observed:Click to read the full article.

API starting material traceability gap after milling / micronization change: data integrity and chromatographic audit trail review steps

Recognizing the early signals of traceability gaps is vital for prompt investigation. Symptoms may include:Click to read the full article.

Cell viability failure during stability testing: regulatory risk assessment and CAPA

Identifying the initial signals of cell viability failure is essential for any effective investigation. Symptoms may vary depending on the specific assay conducted and the cell types involved, but common…

API residual solvent OOS after re-crystallization parameter adjustment: how to justify reprocessing vs rejection to FDA/EMA inspectors

The first step in addressing an OOS result is identifying the symptoms or signals that triggered the investigation. Typical signals to monitor may include:Click to read the full article.

Aseptic manipulation deviation during ATMP manufacturing: inspection-ready investigation package

Detection of deviations is an essential first step in the investigation process, often indicated by specific symptoms or signals observed on the manufacturing floor or within the laboratory setting. Early…

API residual palladium OOS during tech transfer to a new site: how to justify reprocessing vs rejection to FDA/EMA inspectors

Symptoms of residual palladium OOS levels typically manifest during quality control (QC) testing. These signals may include inconsistencies in test results compared to established specifications as detailed in the relevant…

Cryopreservation failure during FDA inspection readiness: regulatory risk assessment and CAPA

The first step in addressing cryopreservation failures is identifying the symptoms or signals indicative of a problem. Common indications include:Click to read the full article.

API co-crystal / salt form inconsistency during CPV trending review: supplier qualification gaps and incoming testing upgrades to close the loop

Identifying the signs of co-crystal or salt form inconsistencies is crucial in preemptively managing quality issues. Symptoms can stem from various stages of production and lead to quality assurance concerns.…